If a drug can be rescued, what exactly should be protected?
The biotechnology sector has traditionally rewarded discovery. Novel targets, promising therapeutic candidates and breakthrough technologies attract attention because they represent the starting point for future products and, ultimately, future revenues. Intellectual property strategies have evolved around the same principle, with patent portfolios typically designed to protect the outputs of successful research and development.
Historically, once a development programme encountered significant safety challenges, the focus often shifted to the next opportunity. Today, advances in biological understanding, data analysis and mechanistic research are creating new opportunities to revisit programmes that may previously have been abandoned. In some cases, understanding why a programme failed can reveal a credible path back into development.
From a scientific perspective, this is an exciting development. From a commercial perspective, however, it immediately raises a different question. If an abandoned drug asset can be rescued, what exactly is being created, and how should intellectual property strategy support it?
Does a scientific solution automatically create a commercial opportunity?
One of the most common misconceptions in drug development is that solving the scientific problem automatically creates a commercial opportunity. In reality, investors, partners and acquirers are asking a different question. They want to know whether the solution is defendable and whether it creates a position that competitors cannot easily replicate.
A successful drug rescue programme may identify a toxicity mechanism, uncover an off-target interaction or establish why a previous development strategy failed. Whilst these insights may provide a route back into development, they do not necessarily guarantee that a commercially attractive asset has been created.
The challenge is therefore broader than solving the science. It involves understanding how the knowledge generated through the drug rescue can be translated into sustainable exclusivity and long-term value.
This is where intellectual property strategy becomes critical.
Is the redevelopment strategy creating fresh exclusivity?
One of the first questions organisations should ask is whether the proposed drug rescue pathway creates new and meaningful opportunities for intellectual property protection.
Many abandoned assets already have a patent history. In some cases, significant patent term may have been consumed before the programme was discontinued. In others, the original patent protection may have limited relevance to the redevelopment strategy being pursued.
Consequently, organisations need to understand what new value is being created. For example, does the redevelopment effort lead to an improved compound with a differentiated profile? Has a new patient population been identified? Does the work support novel treatment approaches, dosing regimens or combination therapies? Could the insights generated support entirely new applications for the underlying technology?
The objective is not simply to identify patentable subject matter. It is to determine whether the redevelopment strategy creates a commercially meaningful exclusivity position cable of justifying future investment.
A scientifically elegant solution may not always be the most commercially attractive solution. Equally, a pathway that creates a stronger and more durable intellectual property position may significantly improve the attractiveness of the programme to investors and partners.
Does the value extend beyond the rescued programme?
Drug rescue programmes often begin with a single asset. However, organisations should consider whether the value they are creating extends beyond the programme itself. Understanding a toxicity mechanism, identifying a safety liability or uncovering a previously unrecognised biological relationship may generate insights that can be applied more broadly. The knowledge created during the drug redevelopment process may influence future programmes, therapeutic areas or discovery efforts.
This creates an important question: Is the objective simply to rescue a product, or is the organisation building a broader position around a class of biological insights?
The answer should influence portfolio strategy. For example, an asset-centric approach may focus primarily on patent protecting the redeveloped therapeutic candidate and associated product-specific innovations. A broader approach may seek to establish intellectual property protection around biomarkers, patient populations, enabling technologies or other innovations cable of supporting multiple future opportunities.
Neither strategy is inherently right or wrong. The important point is ensuring that the intellectual property strategy reflects the nature of the business that is being created.
Where should the intellectual property budget be invested?
One of the practical realities of intellectual property strategy is that resources are finite.
A successful drug rescue programme can generate numerous potential inventions. For example, redesigned compounds, diagnostics, treatment methods, dosing regimens and platform technologies may all emerge from a deeper understanding of the underlying science.
Yet not every invention will deliver the same commercial return. The most sophisticated intellectual property strategies are therefore not necessarily those that pursue the largest number of patent filings. They are the intellectual property strategies that allocate resources to the opportunities most capable of supporting future value creation.
This requires organisations to think carefully about which innovations are likely to matter most to future investors, partners and competitors. In some circumstances, the strongest intellectual property position may sit around protecting a redesigned therapeutic candidate. In others, the more valuable opportunity may arise from surrounding innovations that create barriers to entry and strengthen the overall commercial proposition.
Prioritisation is therefore just as important as identification.
What should be patented and what should remain confidential?
Another consideration relates to the balance between patents and confidential know-how.
Many organisations instinctively focus on patent protection, but not every source of competitive advantage is best protected through disclosure of the innovation in a patent specification.
Drug rescue programmes generate proprietary knowledge relating to datasets, analytical methodologies, biological mechanisms and decision-making frameworks. In some situations, retaining elements of this knowledge as confidential know-how may provide a stronger and more durable advantage than patent protection alone.
The most effective strategies frequently involve a combination of approaches. Patents may be used to protect products and commercially visible innovations, whilst keeping proprietary know-how confidential protects the underlying capabilities that enable future opportunities to be identified and developed.
The challenge is not deciding whether protecting through patents or keeping proprietary know-how confidential is preferable. The challenge is determining how patents and confidential proprietary know-how can work together to reinforce competitive advantage.
Should intellectual property strategy influence the science?
Perhaps the most interesting question of all is whether intellectual property strategy should influence redevelopment decisions themselves.
Drug rescue programmes often present multiple potential pathways forward. Several technically viable solutions may exist, each with different scientific, regulatory and commercial characteristics.
In these circumstances, intellectual property strategy can play an important role in decision making.
If one pathway creates stronger exclusivity, broader partnering opportunities or a more attractive investment proposition than another, should that influence the direction of development? Many organisations would argue that it should. This does not mean intellectual property strategy drives the science. However, it does recognise that scientific and commercial success are closely linked and that the strongest opportunities are often created when both considerations are evaluated together.
Beyond rescue: Building long-term value
Drug rescue programmes challenge the assumption that value is created only at the point of discovery. Value can also be created through understanding. The ability to explain why a programme failed, establish a viable path forward and translate that knowledge into commercially meaningful innovation can itself become a powerful source of competitive advantage.
The question is not whether a rescued asset should be protected. Of course it should. The more interesting question is whether organisations are using intellectual property protection strategically enough to maximise the value created during the rescue process itself.
If your organisation is involved in drug rescue, asset redevelopment or the broader challenge of creating value from previously abandoned research programmes, our patent experts would be delighted to discuss how intellectual property strategy can support those activities.
